Drug Profile
GLG 801
Alternative Names: GLG-801Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute
- Developer GLG Pharma
- Class Antineoplastics; Small molecules; Urologics
- Mechanism of Action STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic lymphocytic leukaemia
- Phase I/II Breast cancer; Solid tumours
- Discontinued Polycystic kidney disease
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Polycystic kidney disease in Poland (PO) (GLP Pharma website; August 2023)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Polycystic-kidney-disease in Poland (PO, Tablet)
- 17 May 2018 Phase-I/II clinical trials in Breast cancer (Refractory metastatic disease, Late-stage disease) in Poland (PO)